Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

FDA recall notice · announced July 5, 2017 · Sanofi-aventis U.s

Class III FDA/FSIS Class III: use is not likely to cause adverse health consequences.

The product

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Reason for recall

Superpotent Drug: high out-of-specification result for magnesium.

Notes

Distribution: Nationwide in the USA, Puerto Rico, and the United Kingdom.
Lot/code information: Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19
Quantity: 2980 bottles
Status: Terminated
Products in this recall event:
- Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, P (D-0926-2017)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.